Show simple item record

dc.contributor.authorMcConnell, E. L.
dc.contributor.authorLiu, Fang
dc.contributor.authorBasit, A.W.
dc.date.accessioned2012-04-24T09:59:02Z
dc.date.available2012-04-24T09:59:02Z
dc.date.issued2009
dc.identifier.citationMcConnell , E L , Liu , F & Basit , A W 2009 , ' Colonic treatments and targets : issues and opportunities ' , Journal of Drug Targeting , vol. 17 , no. 5 , pp. 335-363 . https://doi.org/10.1080/10611860902839502
dc.identifier.issn1061-186X
dc.identifier.otherPURE: 815752
dc.identifier.otherPURE UUID: de8bf97c-c13f-4c74-9fb0-2487a64594a5
dc.identifier.otherScopus: 69149099286
dc.identifier.urihttp://hdl.handle.net/2299/8417
dc.description.abstractThe colon provides a plethora of therapeutic opportunities. There are multiple disease targets, drug molecules, and colon-specific delivery systems to be explored. Clinical studies highlight the potential for systemic delivery via the colon, and the emerging data on the levels of cell membrane transporters and metabolic enzymes along the gut could prove advantageous for this. Often efflux transporters and metabolic enzyme levels are lower in the colon, suggesting a potential for improved bioavailability of drug substrates at this site. The locoregional distribution of multiple metabolic enzymes (including cytochromes), efflux transporters (including P-glycoprotein and breast cancer resistance proteins), and influx transporters (including the solute carrier family) along the intestine is summarized. Local delivery to the colonic mucosa remains a valuable therapeutic option. New therapies that target inflammatory mediators could improve the treatment of inflammatory bowel disease, and old and new anticancer molecules could, when delivered topically, prove to be beneficial adjuncts to the current systemic or surgical treatments. New issues such as pharmacogenomics, chronotherapeutics, and the delivery of prebiotics and probiotics are also discussed in this review. Targeting drugs to the colon utilizes various strategies, each with their advantages and flaws. The most promising systems are considered in the light of the physiological data which influence their in vivo behavioren
dc.language.isoeng
dc.relation.ispartofJournal of Drug Targeting
dc.titleColonic treatments and targets : issues and opportunitiesen
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionDepartment of Pharmacy
dc.description.statusPeer reviewed
dcterms.dateAccepted2009
rioxxterms.versionofrecordhttps://doi.org/10.1080/10611860902839502
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record